Business Today
Subscribe
NRICareer & JobsUS NewsMake In IndiaIn PicsWeatherFuel PricesPMS TodayBT Reels
BT India at 100BT Infra SummitEY Business Today Hidden Gems 2026
Search
Advertisement
Business News
wockhardt

Wockhardt

 

More Stories on Wockhardt
Tata Steel, Hindustan Copper, Lloyds Engineering shares: Expert weighs in; names top pharma, broking bets

Tata Steel, Hindustan Copper, Lloyds Engineering shares: Expert weighs in; names top pharma, broking bets

Sep 07, 2026, 06:11 PM IST

In the pharma segment, the market expert advised adding Wockhardt, Glenmark Pharmaceuticals and Dr Reddy's Laboratories on declines.

Wockhardt’s Profit Returns As Novel Antibiotic Business Gains Momentum

Wockhardt’s Profit Returns As Novel Antibiotic Business Gains Momentum

Aug 13, 2026, 03:17 PM IST

Wockhardt has returned to profit in Q1 FY27, reporting a PAT of ₹107 crore against a loss of ₹108 crore a year earlier. Revenue rose 26% to ₹929 crore, while EBITDA increased 86% to ₹188 crore. The company has also launched the Wockhardt Antibiotic Academy, a platform focused on antimicrobial resistance, antibiotic stewardship and scientific exchange among clinicians. Wockhardt says around 10 lakh patients die annually in India from multidrug-resistant infections. Business Today TV speaks to Dr Habil Khorakiwala, Founder Chairman, Wockhardt, on the company’s return to profit, its growth strategy, novel antibiotics, antimicrobial resistance and the commercial opportunity in infectious diseases.

Pharma stocks: Sun Pharma, Biocon, Dr Reddy's, Torrent Pharma slip on Trump's generic drug tariff plan

Pharma stocks: Sun Pharma, Biocon, Dr Reddy's, Torrent Pharma slip on Trump's generic drug tariff plan

Jul 23, 2026, 10:42 AM IST

Among the notable losers were Sun Pharmaceutical Industries Ltd, Biocon Ltd, Torrent Pharmaceuticals Ltd, Dr Reddy's Laboratories Ltd, Cipla Ltd, Wockhardt Ltd, Zydus Lifesciences Ltd, IPCA Laboratories Ltd, Gland Pharma Ltd, Alkem Laboratories Ltd and Ajanta Pharma Ltd.

How Zaynich will drive Wockhardt’s next phase of growth

How Zaynich will drive Wockhardt’s next phase of growth

Jul 07, 2026, 01:56 PM IST

After spending nearly Rs 6,800 crore and more than two decades, Wockhardt has achieved what no Indian pharmaceutical company has before: US FDA approval for a novel drug discovered and developed in-house. Zaynich is expected to drive Wockhardt's next phase of growth after it returned to profitability in FY26.

Full-Circle Moment: Why Vedanta is more than a corporate restructuring story

Full-Circle Moment: Why Vedanta is more than a corporate restructuring story

Jul 06, 2026, 12:39 PM IST

Agarwal’s business journey has come full circle, unlocking value through a deep corporate restructuring.

Here's how this Indian company's antibiotic became the first to receive US FDA

Here's how this Indian company's antibiotic became the first to receive US FDA

Jun 03, 2026, 07:02 PM IST

Wockhardt is betting big on a space the world's largest pharmaceutical companies have abandoned.

Wockhardt R&D Shift: Dr Khorakiwala On How Zaynich Success Transforms Biotech Capital Allocation

Wockhardt R&D Shift: Dr Khorakiwala On How Zaynich Success Transforms Biotech Capital Allocation

Jun 03, 2026, 12:37 PM IST

In an exclusive interview, Wockhardt Founder Chairman Dr. Habil Khorakiwala confirms a major transformation toward becoming a research-driven global biopharma pioneer. Following the breakthrough success and regulatory approvals for its novel antibiotic Zaynich, the company is pivoting its capital allocation strategy to aggressively fund its innovative R&D pipeline over the next three to five years. While global pharma giants scaled back antibiotic research due to weak economic returns, Wockhardt leveraged the lack of competition to target antimicrobial resistance, aiming to establish India as a premier innovation hub for global antibiotic discovery.

Wockhardt Shares Hit Record High As It Secures USFDA Approval For A Novel Antibiotic Zaynich

Wockhardt Shares Hit Record High As It Secures USFDA Approval For A Novel Antibiotic Zaynich

Jun 02, 2026, 03:02 PM IST

Wockhardt Shares Hit Record High As It Secures USFDA Approval For A Novel Antibiotic Zaynich

Zaynich's U.S. FDA Approval Marks Breakthrough For Indian Pharma

Zaynich's U.S. FDA Approval Marks Breakthrough For Indian Pharma

Jun 02, 2026, 02:16 PM IST

Wockhardt has received US FDA approval for Zaynich (cefepime and zidebactam), a novel intravenous antibiotic for the treatment of adults with complicated urinary tract infections, including pyelonephritis. The approval follows positive results from the Phase 3 ENHANCE-1 study, where Zaynich demonstrated superior efficacy to meropenem. Wockhardt said Zaynich is the first new chemical entity fully developed and commercialised by an Indian pharmaceutical company to receive U.S. FDA approval. The company recently secured approval for the antibiotic in India and has also submitted a marketing authorisation application in Europe.

Glenmark, Auro Pharma, Wockhardt: Top pharma stocks to trade— Key levels, targets & more

Glenmark, Auro Pharma, Wockhardt: Top pharma stocks to trade— Key levels, targets & more

Jun 02, 2026, 08:36 AM IST

An analyst from Anand Rathi said that Wockhardt has witnessed a strong rally and is currently trading significantly above its 20-day and 50-DEMA, indicating an extended price structure.

Wockhardt share price soars 19% to hit fresh record high; here's why

Wockhardt share price soars 19% to hit fresh record high; here's why

Jun 01, 2026, 09:29 AM IST

Wockhardt share price rose 19.17 per cent to hit a high of Rs 2,420 on BSE. This was in addition to a 14.70 per cent jump on Friday.

Load More

MARKET BUZZ

  • NSE
  • BSE
  • No data found
SUBSCRIBE TO
BUSINESS TODAY MAGAZINE
Subscribe Now
Already a subscriber?Login

LATEST

Read more

MARKET TODAY

TOP VIDEOS